KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1013902
Abstract: KRAS mutations are among the most commonly occurring mutations in cancer. After being deemed undruggable for decades, KRAS G12C specific inhibitors showed that small molecule inhibitors can be developed against this notorious target. At the… read more here.
Keywords: kras g12d; targeted therapies; pancreatic cancer; g12d targeted ... See more keywords